Vera set for full FDA approval of Trutakna after late-stage trial win
Vera Therapeutics NASDAQ:VERA added more than 10% in premarket trading on Tuesday after announcing plans to seek full FDA approval for its lead asset Trutakna following a late-stage trial win in primary IgA nephropathy, an immune-mediated kidney disease.The once-weekly injectable was approved in th…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.